PT - JOURNAL ARTICLE AU - Prowse, Thomas A. A. AU - Purcell, Tara AU - Baía-da-Silva, Djane Clarys AU - Sampaio, Vanderson AU - Monteiro, Wuelton Marcelo AU - Wood, James AU - Mueller, Ivo AU - McVernon, Jodie AU - Lacerda, Marcus V. G. AU - Ross, Joshua V. TI - INFERRED RESOLUTION THROUGH HERD IMMMUNITY OF FIRST COVID-19 WAVE IN MANAUS, BRAZILIAN AMAZON AID - 10.1101/2020.09.25.20201939 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.25.20201939 4099 - http://medrxiv.org/content/early/2020/09/27/2020.09.25.20201939.1.short 4100 - http://medrxiv.org/content/early/2020/09/27/2020.09.25.20201939.1.full AB - INTRODUCTORY PARAGRAPH As in many other settings, peak excess mortality preceded the officially reported ‘first wave’ peak of the COVID-19 epidemic in Manaus, Brazil, reflecting delayed case recognition and limited initial access to diagnostic testing. To avoid early information bias, we used detailed age and gender stratified death certificate and hospitalisation data to evaluate the epidemic’s trajectory and infer the cause of its decline using a stochastic model. Our results are consistent with heterogenous transmission reducing over time due to the development of herd immunity. Relative to a baseline model that assumed homogenous mixing across Manaus, a model that permitted a small, self-isolated population fraction raised the estimated herd-immunity threshold from 28% to 30% and reduced the final attack rate from 86% to 65%. In the latter scenario, a substantial proportion of vulnerable, older individuals remained susceptible to infection. Given uncertainties regarding the distancing behaviours of population subgroups with different social and economic characteristics, and the duration of sterilising or transmission-modifying immunity in exposed individuals, we conclude that the potential for epidemic outbreaks remains, but that future waves of infection are likely to be much less pronounced than that already experienced.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTAAP is supported by the NHMRC Centre for Research Excellence in Policy Relevant Infectious Disease Simulation and Mathematical Modelling. JM is supported by an NHMRC Principal Research Fellowship GNT1117140. IM is supported by an NHMRC Principal Research Fellowship GNT1155075.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved by the Fundacao de Medicina Tropical Dr Heitor Vieira Dourado Ethics Review Board (Approval 4.033.218).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data/code is provided as Supplementary Data with the paper. This will be available with the paper when published.